Center for Advanced Preclinical Research (CAPR)
The NCI Center for Advanced Preclinical Research (CAPR), contractually operated and managed by SAIC-Frederick, Inc., has a cancer translational research-centered mission to facilitate the contribution of genetically engineered mouse models (GEMMs) and other relevant mouse cancer models to the improvement in overall preclinical drug development systems, including improvements to the process of selecting novel therapeutics for clinical trials and developing relevant biomarkers for treatment selection and evaluation. The CAPR mission includes the strategy development for predictive preclinical research with the aim to facilitate their routine application in clinical research in order to achieve optimal outcomes in the management of cancer diseases.
CAPR achieves its mission through internal projects focused on applied preclinical development and through extensive collaborative partnerships (both private and public) that are focused on therapeutic and biomarker development. Organizations include pharmaceutical and biotechnology companies, clinical research and academic institutes, bioinformatics companies, and others.
Learn more about the CAPR program, available genetically engineered mouse models (GEMMs) of cancer available through CAPR, and the supporting infrastructure and technologies of the Laboratory Animal Sciences Program (LASP), the Genomics Research Center, and the Center for Protein and Metabolite Research.
CAPR has recently introduced the iGXT Platform™, a new preclinical-clinical cancer drug development platform involving molecular modeling with integrated GEMMs and patient-tumor xenograft models as part of human cancer clinical trials to guide patient therapy.
For additional information on CAPR and iGXT Platform™ partnership opportunities, please contact:
Bruce Crise, PhD
Director Business Development
Frederick National Laboratory for Cancer Research